About Us
CELLAAX is a clinical-stage biopharmaceutical company engaged in the discovery, research, development and commercialisation of human cell therapies and immunotherapies.
Vision
- To contribute to human welfare by application of biocellular engineering in research, development, and manufacture of cells to restore health and extend life.
- To direct our growth in the areas of biocellular engineering where we display maximum strength and ability; to gather people and facilities that tend to augment these areas; to continuously build on these areas through education and knowledge assimilation.
- To strive without reserve for the greatest possible reliability and quality; to be the unsurpassed standard of comparison and to be recognized as a company of dedication, honesty, integrity, and service.
Mission
Our Story
An offer of great hope,
transformative for all mankind
We were founded in 2019 through our smart alliance with 23 Century International Life Science Centre, an industry leader and manufacturer of high quality stem cell and immunology treatments in South East Asia. This alliance has allowed us to leverage on the vast expertise and innovation from 23 Century to bring us closer to industry advancement and commercialisation.
CELLAAX brings together expertise, scientists and researchers to help accelerate the growth of human cell therapies and immunotherapy treatments in Malaysia. With our growing pipeline and leading technology, we aim to build a fully integrated company leveraging on modern capacities to manufacture and deliver transformative human cell therapy products of high industry standards to pivot us towards global success and as a preferred destination with expertise in human cell therapy treatments within the region.
Our focus as a team is to bring together
world class expertise in science, invention, innovation and investment
to accelerate the growth of human cell therapy in the region
Founder & CEO
Alex Wong
As the revolution in medicine unfolds before us with ever developing new frontiers in human cell therapy treatments, CELLAAX is at the forefront of bringing hope and new possibilities to diseases, once incurable.
We genuinely believe in our mission to regenerate life around the world and extending life through our strong belief in the power of technology in biomedical engineering.
We have a diverse team of experts who serve the pledge of excellence in this frontier. The vast experiences, adaptability and medical retrospectives encourage us to strive without reserve for the greatest possible recognition in this industry. We hold each other accountable, act with integrity, and make quality of life our highest priority.
We welcome you to new possibilities and invite you to reimagine the future with us.
Founder & Chief of Development Sciences
Angelina Tiah
The sudden outbreak of the COVID-19 virus sent the world into a global pandemic. Now more than ever, it has heightened our awareness on the importance of our health and overall being. Each of us were forced to rethink our health, as our quality of life depends highly on the state of it.
At CELLAAX, quality of life is what drives us. Throughout the course of the pandemic, our dedicated team of medical experts and scientists continued the research and development cell therapies and immunotherapies at our state-of-the-art cGMP laboratory here in the heart of Kuala Lumpur.
Our strategic alliance with 23 Century Life Science Center, who partner with Beike Biotechnology, the world’s largest stem cell producer based in Shenzhen, China have given us the push we need to expand the boundaries of healthcare and redefine what is and isn’t possible.
Keeping pace with this vigorous progress, CELLAAX is continuously updating our equipment and services in order to offer the latest and best services in high-tech medical care. Our recent developments include our patented drug to counter Retinitis Pigmentosa, a genetic defect which causes blindness.
These are one of the many milestones we celebrate here at CELLAAX, and with our continued efforts in research and development, we only see possibilities for a future of life changing outcomes.
Chief Investment Officer
Bernard Seah
Despite the circumstances brought about the world over as a result of the COVID-19 outbreak, medicine continues to triumph as we peak in health and sciences. As reported by the Global Database of Regenerative Medicine Investors 2021, the year 2020 alone saw regenerative medicine industries raising approximately $11 billion.
The industry of human cell therapy has seen monumental growth as it is now able to yield desired results and outcomes that are transformative in nature and providing cures to diseases – once thought to be untreatable.
We have successfully brought the largest cell manufacturer in Southeast Asia to our shores. We have an upcoming specialist facility near completion in the northern territory of Malaysia, which is set to provide a new holistic experience in our treatments.
Our onward expansion plans are looking extremely promising, and we are ready to bring the best of human cell therapy and biopharmaceuticals to new heights in Malaysia and the Southeast Asia region.
We believe in collaborative partnership to bring you transformative solutions like never before
Our Partnership with
23 Century International Life Science Centre
At CELLAAX, we hold ourselves to the highest industry standards in our research and development of human cell therapies. This is made possible through our strategic alliance with 23 Century International Life Science Centre.
Our dynamic partnership is unique and allows us to leverage on collective expertise, crucial for not only for our research and development, but in our commercialization process.
23 Century International Life Science Centre operates the largest cGMP cell manufacturing laboratory of more than 15,000 sqft in Southeast Asia. Together, we believe this will enable us to advance our development programs and meet our expansion plans with both speed and scale.